NVO - Eli Lilly Novo eyeing obesity meds for kids as young as six
2023-10-20 09:04:17 ET
More on Eli Lilly, Novo, etc.
- Eli Lilly: The GLP-1 Opportunity, While Increasingly Recognized, Is Vastly Underestimated
- Eli Lilly: Do Not Chase This Stock Over The Cliff
- Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase
- Eli Lilly reportedly hit by illicit versions of next-gen weight loss drug
- Eli Lilly files complaint over alleged fake versions of diabetes drug Mounjaro
For further details see:
Eli Lilly, Novo eyeing obesity meds for kids as young as six